GlassScriptPhysician profile
Richard S Rosenthal
NPI 1447364286
$24,032.24
in general payments reported to CMS, 2019-2025
13 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $614 · 2021: $1,360 · 2022: $2,304 · 2023: $17K · 2024: $367 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,249 · Travel and Lodging: $2,915 · Food and Beverage: $1,523 · Consulting Fee: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,248.64 |
| Travel and Lodging | $2,914.89 |
| Food and Beverage | $1,523.19 |
| Consulting Fee | $1,462.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,661.15 | 2019-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $7,328.25 | 2023 | |
| Amgen INC. | $1,577.08 | 2024-2025 | Tepezza, Prolia |
| Alexion Pharmaceuticals, INC. | $1,568.99 | 2020-2024 | Strensiq |
| Medtronic, INC. | $160.47 | 2024-2025 | Minimed 780g |
| Dexcom, INC. | $152.96 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $129.10 | 2019 | |
| Merck Sharp & Dohme LLC | $114.27 | 2020 | |
| Amryt Pharma Holdings LTD | $84.85 | 2023 | Mycapssa |
| Xeris Pharmaceuticals, INC. | $82.76 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.02 | 2023 | Jardiance |
| Novo Nordisk INC | $74.99 | 2025 | |
| Abbott Laboratories | $15.35 | 2024 | Freestyle Libre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rosenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.